No abstract

These consensus guidelines will help to standardize and simplify the treatment of IH with oral propranolol across the U.K. and assist in clinical decision-making.

References1 McFadden JP, Baker BS, Powles AV, Fry L. Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 2009; 160:929-37. 2 Ting KM, Rothaupt D, McCormick TS et al. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol 2000; 114:706-11. 3 Manabe R, Oh-e N, Sekiguchi K. Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem 1999; 274:5919-24. 4 Bata-Csorgo Z, Cooper KD, Ting KM et al. Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J Clin Invest 1998; 101:1509-18.5 Lasarte JJ, Casares N, Gorraiz M et al. The extra domain A from fibronectin targets antigens to TLR-4 expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007; 178:748-56. 6 Su S-L, Tsai C-D, Lee C-H et al. Expression and regulation of Toll-like receptor 2 by IL-b and fibronectin fragments in human articular chondrocytes. Osteoarthritis Cartilage 2005; 13:879-86. 7 Lyakh L, Trinchieri G, Provezza L et al. Regulation of interleukin-12 ⁄ interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008; 226:112-31. 8 Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159 (Suppl. 2):10-17. 9 White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol 2008; 216:1-14. 10 Schoneveld AH, Hoefer I, Sluitjer JP et al. Atherosclerotic development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 2008; 197:95-104.common among dermatology patients. It is important to be aware of the effects of melanotan on pre-existing MN and as a trigger for new MN. Our patient experienced both. We submitted our case as the first report in the dermatology literature on eruptive naevi following melanotan injections. Since then, a case of eruptive naevi after self-administration of synthetic a-MSH has been published. 6 References 1 Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ 2009; 338:b566.